RT Journal Article
SR Electronic
T1 Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.05.20113738
DO 10.1101/2020.06.05.20113738
A1 Estela Moreno-García
A1 Verónica Rico
A1 Laia Albiach
A1 Daiana Agüero
A1 Juan Ambrosioni
A1 Marta Bodro
A1 Celia Cardozo
A1 Mariana Chumbita
A1 Lorena De la Mora
A1 Nicole García-Pouton
A1 Carolina Garcia-Vidal
A1 Ana González-Cordón
A1 Marta Hernández-Meneses
A1 Alexy Inciarte
A1 Montse Laguno
A1 Lorna Leal
A1 Laura Linares
A1 Irene Macaya
A1 Fernanda Meira
A1 Josep Mensa
A1 Antonio Moreno
A1 Laura Morata
A1 Pedro Puerta-Alcalde
A1 Jhon Rojas
A1 Montse Solá
A1 Berta Torres
A1 Manuel Torres
A1 Adrià Tomé
A1 Pedro Castro
A1 Sara Fernández
A1 Josep Maria Nicolás
A1 Alex Almuedo-Riera
A1 Jose Muñoz
A1 Mariana Jose Fernandez-Pittol
A1 Maria Angeles Marcos
A1 Dolors Soy
A1 José Antonio Martínez
A1 Felipe García
A1 Alex Soriano
YR 2020
UL http://medrxiv.org/content/early/2020/06/05/2020.06.05.20113738.abstract
AB Background In some patients the immune response triggered by SARS-CoV-2 is unbalanced, presenting an acute respiratory distress syndrome which in many cases requires intensive care unit (ICU) admission. The limitation of ICU beds has been one of the major burdens in the management worldwide; therefore, clinical strategies to avoid ICU admission are needed.Objective We aimed to describe the influence of tocilizumab on the need of transfer to ICU or death in non-critically ill patients.Methods A retrospective study of 171 patients with SARS-CoV-2 infection that did not qualify as requiring transfer to ICU during the first 24h after admission to a conventional ward, were included. The criteria to receive tocilizumab was radiological impairment, oxygen demand or an increasing of inflammatory parameters, however, the ultimate decision was left to the attending physician judgement. The primary outcome was the need of ICU admission or death whichever came first.Results 77 patients received tocilizumab and 94 did not. The tocilizumab group had less ICU admissions (10.3% vs. 27.6%, P= 0.005) and need of invasive ventilation (0 vs 13.8%, P=0.001). In multivariable analysis, tocilizumab remained as a protective variable (OR: 0.03, CI 95%: 0.007-0·1, P=0.0001) of ICU admission or death.Conclusion Tocilizumab in the early stages of the inflammatory flare, could reduce ICU admissions and mechanical ventilation use. The mortality rate of 10.3% among patients receiving tocilizumab appears to be lower than other reports.Clinical implication Our results suggest that tocilizumab administered to non-critically ill patients could reduce ICU admissions and mortality.Capsule summary Tocilizumab administered to non-critically ill patients with SARS-CoV-2 infection in the early stages of the inflammatory flare, could reduce an important number of ICU admissions and mechanical ventilation use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding to declareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Committee of the Hospital Clinic of Barcelona approved the study and due to the nature of retrospective chart review, waived the need for inform consent from individual patients (Comite Etic Investigacio Clinica; HCB/2020/0273).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of this study will be available upon request to the corresponding author.